A year in review: new treatments and expanded indications in dermatology in 2024

J Dermatolog Treat. 2025 Dec;36(1):2456528. doi: 10.1080/09546634.2025.2456528. Epub 2025 Jan 27.

Abstract

Methods: A literature search was conducted on Drugs@FDA: FDA-Approved Drugs for the year 2024 to identify new dermatologic treatments.

Results: In 2024, the FDA approved seven new dermatologic therapies and expanded the indications for seven current therapies. These therapies treat conditions such as atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, molluscum contagiosum, and alopecia areata, among others. Some of these advancements converge dermatology with rheumatology, gastroenterology, and oncology, which continue to transform therapy for patients with multiple diseases.

Conclusion: This paper provides a comprehensive overview of these developments and their implications for clinical practice.

Keywords: FDA approvals; biologic therapies; expanded indications; immunotherapy; topical therapy.

Publication types

  • Review

MeSH terms

  • Dermatologic Agents* / therapeutic use
  • Dermatology* / trends
  • Drug Approval
  • Humans
  • Skin Diseases* / drug therapy
  • United States
  • United States Food and Drug Administration

Substances

  • Dermatologic Agents